{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:58:32Z","timestamp":1792184312858,"version":"4.4.0"},"reference-count":23,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T00:00:00Z","timestamp":1685318400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Beijing Municipal Science & Technology Committee","award":["Z211100003521019"],"award-info":[{"award-number":["Z211100003521019"]}]},{"name":"Guangzhou Recomgen Biotech Co., Ltd"},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870905"],"award-info":[{"award-number":["81870905"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171272"],"award-info":[{"award-number":["82171272"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Hospitals Authority","award":["PX2022019"],"award-info":[{"award-number":["PX2022019"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Stroke Vasc Neurol"],"accepted":{"date-parts":[[2023,5,1]]},"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background and purpose<\/jats:title>\n                    <jats:p>Recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA) was not inferior to alteplase for ischaemic stroke within 4.5\u2009hours. Our study aimed to investigate the efficacy and safety of rhTNK-tPA in patients who had an ischaemic stroke due to large vessel occlusion (LVO) of anterior circulation beyond 4.5\u2009hours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and design<\/jats:title>\n                    <jats:p>Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-III (TRACE III) is a multicentre, prospective, randomised, open-label, blind endpoint, controlled clinical trial. Patients who had an ischaemic stroke due to anterior circulation LVO (internal carotid artery, middle cerebral artery M1 and M2 segments) within 4.5\u201324\u2009hours from last known well (including wake-up stroke and no witness stroke) and with salvageable tissue (ischaemic core volume &lt;70\u2009mL, mismatch ratio \u22651.8 and mismatch volume \u226515\u2009mL) based on CT perfusion or MRI perfusion-weighted imaging (PWI) were included and randomised to rhTNK-tPA 0.25\u2009mg\/kg (single bolus) to a maximum of 25\u2009mg or standard medical therapy. Specially, we will exclude patients who are intended for direct thrombectomy. All will be followed up for 90 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study outcomes<\/jats:title>\n                    <jats:p>Primary efficacy outcome is modified Rankin Scale (mRS) score \u22641 at 90 days. Secondary efficacy outcomes include ordinal distribution of mRS at 90 days, major neurological improvement defined by a decrease \u22658 points compared with the initial deficit or a score \u22641 on the National Institutes of Health Stroke Scale (NIHSS) at 72 hours, mRS score \u22642 at 90 days, the rate of improvement on Tmax &gt;6\u2009s at 24 hours and NIHSS score change from baseline at 7\u2009days. Safety outcomes are symptomatic intracerebral haemorrhage within 36 hours and mortality at 90 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>TRACE III will provide evidence for the efficacy and safety of rhTNK-tPA in patients who had an ischaemic strokes due to anterior circulation LVO beyond 4.5\u2009hours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05141305\">NCT05141305<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/svn-2023-002310","type":"journal-article","created":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T10:00:29Z","timestamp":1685354429000},"page":"82-89","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open-label, controlled trial"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct05141305","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03785678","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04797013","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03785678","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04454788","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1353-2295","authenticated-orcid":false,"given":"Yunyun","family":"Xiong","sequence":"first","affiliation":[{"name":"Neurology, Beijing Tiantan Hospital, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce C V","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Medicine and Neurology, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Fisher","sequence":"additional","affiliation":[{"name":"Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee H","family":"Schwamm","sequence":"additional","affiliation":[{"name":"Department of Neurology and Comprehensive Stroke Center, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Parsons","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of New South Wales South Western Sydney Clinical School, Liverpool, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8591-4105","authenticated-orcid":false,"given":"Hao","family":"Li","sequence":"additional","affiliation":[{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3082-6789","authenticated-orcid":false,"given":"Yuesong","family":"Pan","sequence":"additional","affiliation":[{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Meng","sequence":"additional","affiliation":[{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8345-5147","authenticated-orcid":false,"given":"Xingquan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Neurology, Beijing Tiantan Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9976-2341","authenticated-orcid":false,"given":"Yongjun","family":"Wang","sequence":"additional","affiliation":[{"name":"Neurology, Beijing Tiantan Hospital, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,5,29]]},"reference":[{"key":"2025082410160987000_9.1.82.1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.109.561787"},{"key":"2025082410160987000_9.1.82.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214300"},{"key":"2025082410160987000_9.1.82.3","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2018-014239"},{"key":"2025082410160987000_9.1.82.4","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000211"},{"key":"2025082410160987000_9.1.82.5","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.111.644963"},{"key":"2025082410160987000_9.1.82.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813046"},{"key":"2025082410160987000_9.1.82.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804355"},{"key":"2025082410160987000_9.1.82.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706442"},{"key":"2025082410160987000_9.1.82.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713973"},{"key":"2025082410160987000_9.1.82.10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.3670"},{"key":"2025082410160987000_9.1.82.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716405"},{"key":"2025082410160987000_9.1.82.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016838","article-title":"Recombinant human Tnk tissue-type plasminogen activator (rhTNK-tPA) versus Alteplase (RT-PA) as fibrinolytic therapy for acute ST-segment elevation myocardial infarction (China TNK STEMI): Protocol for a randomised, controlled, non-inferiority trial","volume":"7","author":"Wang","year":"2017","journal-title":"BMJ Open"},{"key":"2025082410160987000_9.1.82.13","doi-asserted-by":"publisher","DOI":"10.1136\/svn-2021-000978"},{"key":"2025082410160987000_9.1.82.14","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0140-6736(22)02600-9","article-title":"Tenecteplase versus Alteplase in acute ischaemic cerebrovascular events (TRACE-2): A phase 3, a multi-centre, open-label, randomised controlled, non-inferiority trial","volume":"401","author":"Wang","year":"2023","journal-title":"The Lancet"},{"key":"2025082410160987000_9.1.82.15","doi-asserted-by":"publisher","DOI":"10.3109\/08037059209077502"},{"key":"2025082410160987000_9.1.82.16","first-page":"666","article-title":"Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018","volume":"51","year":"2018","journal-title":"Chin J Neurol"},{"key":"2025082410160987000_9.1.82.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0804656"},{"key":"2025082410160987000_9.1.82.18","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.95.11.2508"},{"key":"2025082410160987000_9.1.82.19","doi-asserted-by":"publisher","DOI":"10.1136\/svn-2020-000457"},{"key":"2025082410160987000_9.1.82.20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1474-4422(08)70044-9","article-title":"Effects of Alteplase beyond 3 H after stroke in the Echoplanar imaging thrombolytic evaluation trial (EPITHET): A placebo-controlled randomised trial","volume":"7","author":"Davis","year":"2008","journal-title":"The Lancet Neurology"},{"key":"2025082410160987000_9.1.82.21","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20976"},{"key":"2025082410160987000_9.1.82.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00484-7"},{"key":"2025082410160987000_9.1.82.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109842"}],"container-title":["Stroke and Vascular Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/svn-2023-002310","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T17:16:20Z","timestamp":1756055780000},"score":1,"resource":{"primary":{"URL":"https:\/\/svn.bmj.com\/lookup\/doi\/10.1136\/svn-2023-002310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,29]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,2,27]]},"published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1136\/svn-2023-002310"],"URL":"https:\/\/doi.org\/10.1136\/svn-2023-002310","relation":{},"ISSN":["2059-8688","2059-8696"],"issn-type":[{"value":"2059-8688","type":"print"},{"value":"2059-8696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,29]]}}}